GEHC 10-K Annual Reports

GE HealthCare Technologies Inc. reported a solid year of revenue growth, with total revenues increasing by 4.8% to $20.625 billion. This growth was primarily driven by strong performance in the Pharmaceutical Diagnostics (PDx) segment, which saw a significant 15.6% revenue increase due to volume, pricing, and the acquisition of Nihon Medi-Physics Co., Ltd. (NMP). The Imaging and Advanced Visualization Solutions (AVS) segments also demonstrated growth, though they experienced some pressure in the China market. The Patient Care Solutions (PCS) segment saw a slight decline in revenue, mainly due to a decrease in Life Support Solutions. The company's operating income increased by 5.3% to $2.763 billion, reflecting improved gross profit despite increased costs for products and services driven by inflation and tariffs. Total operating expenses decreased, mainly due to reduced Spin-Off and separation costs, and a decrease in R&D spending as certain programs achieved milestones. The company also announced a significant agreement to acquire Intelerad for $2.3 billion, which is expected to enhance its imaging offerings and expand its reach into outpatient settings. Financially, the company ended the year with a strong cash position and managed its debt effectively.

GE HealthCare Technologies Inc. (GEHC) reported robust performance for the fiscal year 2024, demonstrating resilience and strategic execution in a dynamic global healthcare market. Total revenues reached $19.67 billion, a slight increase of 1% year-over-year, driven primarily by growth in services and a strong performance in the Pharmaceutical Diagnostics (PDx) segment. Despite a 1% dip in the Imaging segment, the company saw growth in Advanced Visualization Solutions (AVS) and Patient Care Solutions (PCS), albeit modest. The PDx segment was a standout, with a 9% revenue increase, fueled by volume, pricing, and new product introductions. Geographically, the company experienced a 5% revenue increase in the United States and Canada (USCAN), while EMEA remained flat. China, however, saw a significant 15% decline in revenues, attributed to the lingering effects of prior stimulus programs and an ongoing anti-corruption campaign impacting healthcare sector spending. The company's profitability also saw improvement, with operating income increasing by 8% and net income attributable to GE HealthCare rising by 27% to $1.99 billion. This was supported by improved gross profit margins, cost productivity initiatives, and a reduction in interest expenses. GEHC remains focused on innovation, particularly in AI and digital solutions, which are integrated across its product lines to enhance patient care and operational efficiency for healthcare providers.

GE HealthCare Technologies Inc. (GEHC) reported a 7% increase in total revenues for the fiscal year ended December 31, 2023, reaching $19.55 billion. This growth was driven by broad-based strength across its four key segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment, the largest contributor, saw a 6% revenue increase, while PDx demonstrated robust 18% growth. Net income attributable to GE HealthCare decreased by 18% to $1.57 billion, primarily due to increased operating expenses related to its standalone company status and higher interest expenses following its separation from GE. Despite the net income dip, the company generated strong free cash flow of $1.72 billion, underscoring its operational efficiency and ability to manage cash. GE HealthCare continues to invest in research and development, with a focus on digital solutions and AI, positioning itself for future growth in the evolving healthcare landscape. Financially, the company ended the year with $2.50 billion in cash and cash equivalents. GEHC's total debt increased to $9.44 billion, largely due to financing activities related to its 2023 spin-off from GE. Management expressed confidence in the company's liquidity, believing existing cash, operating cash flow, and credit facilities will be sufficient to meet its needs for the next 12 months. The company also continues to navigate global economic and geopolitical uncertainties, as noted in its risk factors, but its diversified product portfolio and global reach provide a degree of resilience.

GE HealthCare Technologies Inc. completed its spin-off from General Electric Company on January 3, 2023, and began trading as an independent public company. The company operates as a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, organized into four key segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). For the fiscal year ended December 31, 2022, GE HealthCare reported total revenues of $18.34 billion, representing a 4% increase (7% organically) compared to the previous year. The company experienced growth in its Imaging and Ultrasound segments, driven by new product introductions and acquisitions, though this was partially offset by unfavorable foreign currency impacts and a decrease in service revenues. Financially, the company reported operating income of $2.52 billion and net income attributable to GE HealthCare of $1.92 billion for 2022, both declining year-over-year primarily due to inflationary cost pressures and increased investments in R&D and commercial activities. The company also significantly increased its debt during the year in preparation for and as a result of the spin-off, with total debt reaching $8.25 billion. Despite these challenges, GE HealthCare generated $2.13 billion in cash from operating activities and remains focused on its strategy of delivering industry-leading innovations, building integrated solutions, and enabling the digitization of healthcare.